Your browser doesn't support javascript.
loading
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Fernandez-Rodriguez, Laura; Cianciaruso, Chiara; Bill, Ruben; Trefny, Marcel P; Klar, Richard; Kirchhammer, Nicole; Buchi, Mélanie; Festag, Julia; Michel, Sven; Kohler, Rainer H; Jones, Elham; Maaske, Andre; Vom Berg, Johannes; Kobold, Sebastian; Kashyap, Abhishek S; Jaschinski, Frank; Dixon, Karen O; Pittet, Mikael J; Zippelius, Alfred.
Afiliación
  • Fernandez-Rodriguez L; Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Cianciaruso C; Department of Pathology and Immunology, University of Geneva, Geneve, Switzerland.
  • Bill R; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Trefny MP; Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • Klar R; Department of Pathology and Immunology, University of Geneva, Geneve, Switzerland.
  • Kirchhammer N; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Buchi M; Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • Festag J; Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Michel S; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.
  • Kohler RH; Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Jones E; Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Maaske A; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.
  • Vom Berg J; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.
  • Kobold S; Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • Kashyap AS; Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Jaschinski F; Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany.
  • Dixon KO; Institute of Laboratory Animal Science, University of Zurich, Zürich, Switzerland.
  • Pittet MJ; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany.
  • Zippelius A; German Center for Lung Research (DZL), German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany.
J Immunother Cancer ; 11(5)2023 05.
Article en En | MEDLINE | ID: mdl-37208130
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor Toll-Like 9 / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor Toll-Like 9 / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suiza